-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-504713-76-00
5
2024-12-03
Dermatitis atopic
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-512895-36-00
5
2024-11-25
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2024-518316-39-00
10
2024-11-18
Acute lymphoblastic leukemia
-
2023-504708-27-00
5
2024-11-02
electronic cigarette cessation
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-503394-37-00
5
2024-10-23
Acute Myeloid Leucaemia
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-508760-29-00
5
2024-10-21
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-508539-30-00
4
2024-10-10
Refractory Focal Onset Epilepsy
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2023-508817-18-00
5
2024-10-08
Perennial Allergic Rhinitis (PAR)
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-509096-16-00
6
2024-07-31
Moderately to Severely Active Crohn’s Disease